Oral Treatment for AMD in Phase 1

X-82 is an oral tyrosine kinase inhibitor that blocks the action of vascular endothelial growth factor and platelet-derived growth factor; might it treat neovascular age-related macular degeneration?

Findings  In this phase 1 dose-escalation study of 35 participants, the most common adverse events attributed to oral X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevation (n = 4). The 71% of participants who tolerated X-82 and completed 6 months of treatment averaged 0.68 intravitreous anti–vascular endothelial growth factor rescue injections, with 60% requiring none.

Meaning  These results justify further study, and a phase 2 trial has completed recruitment.

Importance  An oral treatment for neovascular age-related macular degeneration would be less burdensome than repeated intravitreous injections. X-82 is an oral tyrosine kinase inhibitor active against vascular endothelial growth factor (VEGF) and platelet-derived growth factor.

For more info:

http://jamanetwork.com/journals/jamaophthalmology/fullarticle/2629570

http://jamanetwork.com/journals/jamaophthalmology/article-abstract/2629569

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: